0001209191-21-068388.txt : 20211207
0001209191-21-068388.hdr.sgml : 20211207
20211207174406
ACCESSION NUMBER: 0001209191-21-068388
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211130
FILED AS OF DATE: 20211207
DATE AS OF CHANGE: 20211207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WALDRON RICHARD A
CENTRAL INDEX KEY: 0001226961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39787
FILM NUMBER: 211477018
MAIL ADDRESS:
STREET 1: 901 MARINERS ISLAND BLVD STE.205
CITY: SAN MATEO
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BioAtla, Inc.
CENTRAL INDEX KEY: 0001826892
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 851922320
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11085 TORREYANA ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-558-0708
MAIL ADDRESS:
STREET 1: 11085 TORREYANA ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-30
0
0001826892
BioAtla, Inc.
BCAB
0001226961
WALDRON RICHARD A
C/O BIOATLA, INC. 11085 TORREYANA ROAD
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
Common Stock
2021-11-30
2021-12-03
4
S
0
2240
23.997
D
146419
D
Common Stock
2021-11-30
2021-12-03
4
S
0
2422
24.676
D
143997
D
Common Stock
2021-11-30
2021-12-03
4
S
0
848
25.379
D
143149
D
Common Stock
2021-12-01
2021-12-06
4
S
0
2332
22.186
D
140817
D
Common Stock
2021-12-01
2021-12-06
4
S
0
4034
23.266
D
136783
D
Common Stock
2021-12-01
2021-12-06
4
S
0
880
24.224
D
135903
D
Common Stock
2021-12-02
2021-12-06
4
S
0
1405
21.741
D
134498
D
Common Stock
2021-12-02
2021-12-06
4
S
0
29
22.471
D
134469
D
Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.
The range of prices for the shares of Common Stock is from $23.33 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $24.33 to $25.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $25.30 to $25.38. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $21.79 to $22.73. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $22.79 to $23.77. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $23.80 to $24.68. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $21.40 to $22.37. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
The range of prices for the shares of Common Stock is from $22.40 to $22.51. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.
/s/ Christian Vasquez, as Attorney-in-Fact for Richard A. Waldron
2021-12-07